UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

Diagnostic yield of sputum induction in patients with pleural tuberculosis at a tertiary care hospital in Karachi

The international journal of tuberculosis and lung disease, 2019-11, Vol.23 (11), p.1213-1216

2019

Volltextzugriff (PDF)

191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S139-S140

2016

Volltextzugriff (PDF)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Annals of oncology, 2019-04, Vol.30, p.ii79-ii80

2019

Volltextzugriff (PDF)

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii410-viii410

2018

Volltextzugriff (PDF)

Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii144

2018

Volltextzugriff (PDF)

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S115-S116

2016

Volltextzugriff (PDF)

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Annals of oncology, 2018-10, Vol.29, p.viii422-viii422

2018

Volltextzugriff (PDF)

A Phase I Study of LGD1069 in Adults with Advanced Cancer

Clinical cancer research, 1999-07, Vol.5 (7), p.1658-1664

1999

Volltextzugriff (PDF)

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC

Annals of oncology, 2004-03, Vol.15 (3), p.410-418

2004

Volltextzugriff (PDF)

Docetaxel (Taxotere) and gemcitabine in combination therapy

Seminars in oncology, 1999-06, Vol.26 (3 Suppl 11), p.19

Rizvi, N A

1999

Volltextzugriff (PDF)

Docetaxel and gemcitabine combinations in non-small cell lung cancer

Seminars in oncology, 1999-10, Vol.26 (5), p.27-31

1999

Volltextzugriff (PDF)

Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer

Clinical cancer research, 1998-06, Vol.4 (6), p.1437-1442

1998

Volltextzugriff (PDF)

An efficient framework for real-time tweet classification

International journal of information technology (Singapore. Online), 2017-06, Vol.9 (2), p.215-221

2017

Volltextzugriff (PDF)

Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy

Mymensingh medical journal : MMJ, 2011-10, Vol.20 (4), p.605

2011

Volltextzugriff (PDF)

Is malnutrition a risk factor of stroke?

Mymensingh medical journal : MMJ, 2015-04, Vol.24 (2), p.373

2015

Volltextzugriff (PDF)

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.1818-1831

2018

Volltextzugriff (PDF)

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii411-viii411

2018

Volltextzugriff (PDF)

1154PA phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1152PSafety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

LBA3Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

LBA6Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

A case report: Leprosy Polyneuritis from Bangladesh

Indian Journal of Basic and Applied Medical Research, 2020-03, Vol.9 (2)

2020

Volltextzugriff (PDF)

439PProspective validation of prognostic scores to improve patient selection for immuno-oncology trials

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1184PPharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1 – 25 von 1.243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.028)
Mit Volltextzugriff
(993)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Diagnostic yield of sputum induction in patients with pleural tuberculosis at a tertiary care hospital in Karachi

191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

A Phase I Study of LGD1069 in Adults with Advanced Cancer

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC

Docetaxel (Taxotere) and gemcitabine in combination therapy

Docetaxel and gemcitabine combinations in non-small cell lung cancer

Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer

An efficient framework for real-time tweet classification

Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy

Is malnutrition a risk factor of stroke?

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors

1154PA phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors

1152PSafety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

LBA3Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

LBA6Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

A case report: Leprosy Polyneuritis from Bangladesh

439PProspective validation of prognostic scores to improve patient selection for immuno-oncology trials

1184PPharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Suchergebnisse filtern